Neuroimmunotherapy with IL-2 and Melatonin for Lung Cancer
Author Information
Author(s): P. Lissonil, E. Tisi, S. Barni, A. Ardizzoni, F. Rovelli, R. Rescaldani, D. Ballabio, C. Benenti, M. Angeli, G. Tancini, A. Conti, G.J.M. Maestroni
Primary Institution: Hospital of Monza
Hypothesis
Can a combination of interleukin-2 and melatonin improve treatment outcomes in advanced non-small cell lung cancer?
Conclusion
The combination of IL-2 and melatonin may be an effective and well-tolerated treatment for metastatic non-small cell lung cancer.
Supporting Evidence
- 4 out of 20 patients showed a partial response to treatment.
- 50% of patients had stable disease after treatment.
- Toxicity was low, with no significant cardiovascular complications.
Takeaway
Doctors tested a new treatment for lung cancer using two medicines, IL-2 and melatonin, and found it helped some patients feel better.
Methodology
The study involved 20 patients receiving IL-2 and melatonin, with treatment cycles and evaluations of clinical response and toxicity.
Potential Biases
Potential biases may arise from the lack of randomization and the subjective nature of clinical response assessments.
Limitations
The study had a small sample size and lacked a control group for comparison.
Participant Demographics
14 males and 6 females, median age 55 years (range 38-70), with various histotypes of lung cancer.
Statistical Information
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website